Bpifrance Large Venture is taking part in the operation together with historic investors(2) that include Fonds Biothérapies innovantes et maladies rares (FBIMR – Fund for Innovative Biotherapies and Rare Diseases), managed by Bpifrance and subscribed by AFM-Téléthon and Fonds national d’amorçage (FNA – National Seed-Stage Fund) as part of the Programme d’investissements d’avenir (PIA – Programme of Investments for the Future).
See Gensight Biologics’ video presentation
In 2015, Bpifrance, the PIA as an operator, allocated €18.5mn to the Sight Again collaborative project. The project was developed by GenSight Biologics, Pixium Vision, and Fondation Voir et Entendre (See and Hear Foundation); its ambition is to restore sight to patients suffering from retinitis pigmentosa at different stages.
(1) ISIN Code: FR0013183985, mnemonic code: SIGHT.
(2) Novartis, Abingworth, Versant, Vitavest, Fidelity, Sphera, Jennison, Healthcap, and Perceptive.